Jersey Shore NJ
FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Oct 2, 2019-- |!| Atlantic City
